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Introduction: The incidence of mesothelioma is rising. First-line 
cisplatin and pemetrexed confers a survival benefit, with a median 
progression-free survival (PFS) of 5.7 months. Sorafenib inhibits 
tyrosine kinases, including receptors for vascular endothelial growth 
factor, which are implicated in mesothelioma pathogenesis by pre-
clinical and clinical data.
Methods: Sorafenib, at 400 mg twice daily, was assessed in a sin-
gle-arm multicenter phase 2 study, using Simon’s two-stage design. 
Eligible patients had received platinum combination chemotherapy 
earlier. The primary endpoint was PFS at 6 months, with secondary 
endpoints, including response rate and metabolic response, assessed 
using fluorodeoxyglucose positron emission tomography. Published 
reference values for PFS in mesothelioma provide a benchmark for 
the null hypothesis of 28% progression-free at 6 months, and for 
moderate or significant clinical activity of 35% or 43% progression-
free at 6 months, respectively.
Results: Fifty-three patients (72%) were treated. Most had 
epithelioid histology. Ninety-three percent of patients had a per-
formance status 0 or 1. Treatment was well tolerated with few 
grade 3 or 4 toxicities. Median PFS was 5.1 months, with 36% of 
patients being progression-free at 6 months. Nine percent of patients 
remained on study beyond 1 year. Changes in fluorodeoxyglucose 
positron emission tomography parameters did not predict clinical 
outcome.
Conclusions: Sorafenib is well tolerated in patients with mesothe-
lioma after completion of platinum-containing chemotherapy. PFS 
of sorafenib compares favorably with that reported for other targeted 
agents, and suggests moderate activity in this disease.
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Malignant mesothelioma is a disease of the mesothelial surfaces of pleural and peritoneal cavities. More than 
80% of cases are pleural, and there is an overwhelming rela-
tionship with exposure to asbestos.1 The incidence of the dis-
ease is predicted to continue to rise in the current decade.2 
Combination platinum chemotherapy with the antifolate 
pemetrexed has become the standard of care as first-line treat-
ment. Median overall survival (OS) is 11.4 and 12.1 months 
in phase 3 trials, which combined third-generation antifolates 
with cisplatin.3,4 In the second-line setting, no standard has yet 
been established.
A significant role for angiogenesis in the evolution of 
mesothelioma has been suggested, both by preclinical in vivo and 
cell-line studies, and by translational data from patient samples. 
Elevated or overexpressed vascular endothelial growth factor 
(VEGF), VEGF-C, fibroblast growth factor-1 and -2 (FGF-1 
and FGF-2), tumor necrosis factor beta, VEGFR-1/FLT-1, 
kinase domain insert receptor/VEGFR-2, and VEGFR-3/FLT-4 
have been associated with mesothelioma.5–8 Local production 
of VEGF leads to receptor phosphorylation in an autocrine 
loop, which can be arrested in vitro with neutralizing antibod-
ies to both VEGF and its receptors.8 Antisense oligonucleotides 
that inhibit VEGF and VEGF-C, antibodies to VEGFR-2 and 
VEGFR-3, and directly conjugated VEGF-diphtheria toxin, 
have all been shown to inhibit mesothelioma cell growth in 
vitro.9 Furthermore, there is an inverse correlation between cir-
culating VEGF and FGF-2 and survival,6,8,10 with higher levels 
of pretreatment VEGF possibly acting as a predictive marker 
for antiangiogenesis in mesothelioma.11 Taken together, this 
evidence provides a rationale for a therapeutic disruption of 
angiogenesis pathways in mesothelioma.
Sorafenib was originally developed as an Raf-1 kinase 
inhibitor.12 It was subsequently found to be a potent inhibitor 
of both wild-type B-Raf, and oncogenic B-Raf V600E 
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serine/threonine kinases, and of the proangiogenic receptor 
tyrosine kinases VEGFR1/2/3, platelet-derived growth factor 
receptor-β, FGFR-1, c-Kit, FLT-3, and RET.13 In xenograft 
models of human colon cancer, and murine and human 
renal-cell carcinoma, sorafenib significantly reduced tumor 
microvascular density.13,14 Combinations of antiangiogenic 
effects, inhibition of signaling through the MAPK pathway, 
and MAPK-independent induction of apoptosis have all been 
shown to contribute to in vivo sorafenib activity in multiple-
tumor xenograft models.15–18 Sorafenib has undergone 
extensive investigation in a range of solid tumors,19–24 and is 
approved for the treatment of clear-cell renal and hepatocellular 
carcinoma.25,26 We conducted a phase 2 study of sorafenib in 
patients with mesothelioma, previously treated with first-line 
pemetrexed plus platinum chemotherapy.
PATIENTS AND METHODS
Eligibility Criteria
Eligible patients had malignant pleural mesothelioma 
not suitable for surgery. Relapse after surgery was allowed. All 
patients had received first-line chemotherapy with pemetrexed 
and platinum. Patients had an Eastern Cooperative Oncology 
Group performance status (PS) of 0 to 2 and measurable dis-
ease according to the Response Evaluation Criteria in Solid 
Tumors (RECIST) criteria modified for mesothelioma.27 
Adequate bone marrow, renal, liver, and coagulation func-
tion, as defined by protocol-mandated laboratory tests within 
7 days of starting the first dosage, were required, and patients 
were excluded in the presence of significant congestive car-
diac failure or arrhythmias requiring antiarrhythmic therapy, 
or other major comorbidity such as uncontrolled hypertension, 
impaired immunity, active infection, coagulopathy, antico-
agulation, thrombosis, or hemorrhage. Prior palliative radio-
therapy was permitted. The study was approved by the U.K. 
national research ethics service, and all patients signed written 
informed consent before commencement of study procedures.
Study Treatment and Evaluation
This was a single-arm phase 2 study of continuous dos-
ing with sorafenib 400 mg twice daily, with a cycle defined 
as 28 days. Dosage interruptions were permitted for toxic-
ity, as were dose reductions (to 400 mg once daily, then to 
400 mg alternate days if required) for any grade 3 or 4 toxic-
ity (excluding hypertension, diarrhea, or rash not adequately 
treated with supportive medication), or for recurrent grade 2 
toxicity after dosage interruption. Patients were reviewed in 
the clinic on days 1 and 15 of the first cycle, and on day 1 
of each subsequent cycle. Safety blood tests, including thy-
roid function and blood pressure observations were performed 
regularly. Treatment was continued until disease progression, 
withdrawal of consent, or unacceptable toxicity.
Baseline disease was imaged by computed tomography 
(CT), with subsequent scans performed at 8-weekly intervals, 
using modified RECIST.27 A subgroup of sequentially recruited 
patients underwent a baseline fluorodeoxyglucose positron 
emission tomography (FDG-PET) scan with low-dose CT at 
baseline, and at 8 weeks after commencing sorafenib.
Statistical Methods
The primary endpoint of the study was progression-free 
survival (PFS) at 6 months. Secondary endpoints were partial 
response rate assessed by CT scan, disease control rate (par-
tial response rate plus stable disease rate), and OS. Change 
in FDG-PET-CT avidity was included as an exploratory 
endpoint. For FDG-PET, changes in maximum standardized 
uptake value, metabolic tumor volume, and total lesion gly-
colysis were assessed before and after 8 weeks of treatment.
Using published reference data for PFS at 6 months, a 
null hypothesis of 28%, and an alternative hypothesis of 43% 
were assumed.28 Accrual of 55 patients was required for a sig-
nificance level of 0.10 with an 80% power to detect whether 
the true 6-month PFS would be more than 43%. A two-stage 
optimum design was used,29 with an initial 19 patients enrolled 
and evaluated for 6-month PFS, planned such that the trial 
would be continued only if six or more of the 19 patients were 
progression-free at 6 months. OS and PFS were estimated using 
the Kaplan–Meier method. Data were collected through an 
electronic database (MedSciNet AB, Stockholm, Sweden), and 
statistical analysis was performed using SSPS. The relationship 
between the changes in FDG avidity and outcome (PFS and 
OS) was assessed using Pearson’s correlation coefficient, using 
SPSS version 20 with a significance level of p equal to 0.05.
RESULTS
Patients Characteristics
Fifty-six patients were recruited at three centers between 
November 2008 and April 2011. Three patients were excluded 
because of ineligibility. Baseline characteristics are shown in 
Table 1. Overall, 77% were men, with 72% having epithelioid 
histology. PS was 1 or better in the greater majority of patients 
(93%). In total, 225 cycles of sorafenib were administered, 
with a median number of four cycles.
Toxicity
All patients were evaluable for toxicity assessment, 
shown in Table 2. The most common grade 3/4 adverse events 
were fatigue (15%), palmar-plantar erythrodysesthesia (13%), 
and rash (9%). Other toxicities, namely diarrhea, mucositis, 
anorexia, alopecia, dysphonia, nausea, vomiting, constipation, 
TABLE 1. Baseline Patient Characteristics
Patient Characteristics
Age (range, yr) 66 (49–82)
Sex (%) Men 41 (72)
Women 12 (23)
Histology (%) Epithelioid 38 (72)
Sarcomatoid 2 (4)
Mixed 8 (15)
Not recorded 5 (9)
Performance status 0 4 (7)
1 45 (85)
2 4 (7)
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dry skin, and pruritis, of any grade occurring in more than 10% 
of patients were typical for sorafenib. Only one grade 4 event 
was recorded—myocardial infarction in a patient previously 
treated for coronary artery disease. There were no deaths 
related clearly to the study drug. At least one dose reduction 
was required in 39% of patients, with a dosage interruption in 
32% of patients. Twenty-one percent of patients required dose 
reduction in the first cycle. Eleven patients (21%) discontinued 
treatment because of toxicity, but most (66%) were withdrawn 
because of disease progression (data not shown).
Efficacy
Nineteen patients completed treatment in the first stage 
of the trial, with six patients being progression-free after 6 
months. Therefore, recruitment of a total of 53 patients con-
tinued in the second stage. Median PFS was 5.1 months 
(95% CI: 3.5–6.7 months), with 36% (95% CI: 22%–49%) of 
patients progression-free at 6 months, and 9% of patients still 
receiving study drug at 1 year (Fig. 1A). Median OS was 9.0 
months (95% CI: 6.7–11.3 months; Fig. 1B).
Three patients had a partial response (6%), with stable 
disease in 30 (56%) at 8 weeks for a disease control rate (partial 
response plus stable disease) of 62%. Eight patients progressed 
(15%) and 12 were not evaluable because of discontinuation of 
study drug before the first disease assessment (Fig. 2).
Functional imaging
Fourteen patients underwent paired FDG-PET-CT 
scans at baseline and 8 weeks, after commencing sorafenib. 
There was no significant correlation between any of the FDG 
quantitative measures and PFS or OS (data not shown).
DISCUSSION
In the evaluation of targeted agents, for which disease 
stabilization may be as important as response, meaningful end-
points need to be defined to ensure that only potentially active 
agents progress to further study. The use of PFS in single-arm 
trials is rational in the phase 2 study of antiangiogenic drugs 
in less common diseases.30 The European Organisation for 
Research and Treatment of Cancer (EORTC) studied nine phase 
2 trials and one phase 3 trial, involving 523 evaluable chemo-
therapy-naive mesothelioma patients. This group was pooled 
to determine PFS at 3, 4, 5, and 6 months as comparators for 
endpoints in subsequent studies.28 These trials were conducted 
in the first-line setting but in an era before the current standard 
of care with platinum doublet chemotherapy was established. 
PFS was derived for three groups of study drug, designated as 
having significant, moderate, or insufficient clinical activity. 
Six-month PFS was determined to be 43% for an agent with 
significant clinical activity, and 35% for moderate activity.28
The primary endpoint of PFS at 6 months of 36% in this 
trial is indicative of moderate clinical activity for sorafenib 
in this disease.28 The comparator PFS values used set a high 
hurdle for this second-line study because they were observed 
in chemotherapy-naive patients. Like other single-agent 
VEGFR-targeted agents in mesothelioma, the response rate 
was low11,31–34 in keeping with a predominantly cytostatic role 
for such agents. RECIST assessment of response in this dis-
ease is less straightforward than for some other solid tumors,27 
and we explored, in a subset of patients, the utility of FDG-
PET parameters as alternative predictors of outcome. None 
of the PET parameters (change in standardized uptake value, 
metabolic tumor volume, or total lesion glycolysis) correlated 
with PFS or OS. However, with a sample size of 14, the power 
to detect a correlation coefficient of r equal to 0.5 is only 46%.
Median PFS in this study was 5.1 months. A number 
of phase 2 trials have studied other single-agent VEGFR-
targeting agents in mesothelioma. Cediranib and sunitinib 
showed median PFS results of 2.6 and 2.7 months, respectively, 
in patients pretreated with platinum.32,35 In chemotherapy-
naive patients, median PFS with vatalanib and sunitinib was 
4.1 and 6.7 months, respectively.33,35 One other trial studied 
sorafenib in a heterogeneous group of 50 evaluable patients, 
60% of whom had been exposed to prior pemetrexed-based 
combination chemotherapy. The response rate was 6% with a 
median PFS of only 3.6 months.31 The higher PFS seen in our 
trial, compared with other VEGFR inhibitors, may indicate 
superior activity for sorafenib than for the other drugs in 
this class tested in mesothelioma, but comparison with this 
last study31 suggests that patient selection is likely to play a 
significant role. All patients treated in our trial were originally 
fit enough to receive platinum-based chemotherapy, all had 
received only one prior line of treatment, and a great majority 
had a PS of less than 1 on enrolment. Nevertheless, 28% 
TABLE 2. Toxicity
Grade  
1/2 (%)
Grade  
3 (%)
Grade  
4 (%)
Grade  
1–4(%)
Fatigue 27 (51) 8 (15) 0 66
Rash 23 (43) 5 (9) 0 53
PPE 16 (30) 7 (13) 0 43
Diarrhea 17 (32) 1 (2) 0 34
Mucositis 16 (30) 2 (4) 0 34
Anorexia 14 (26) 4 (8) 0 34
Alopecia 12 (23) 0 0 23
Dysphonia 9 (17) 0 0 17
Nausea 7 (13) 2 (4) 0 17
Constipation 7 (13) 0 0 13
Dry skin 7 (13) 0 0 13
Puritis 6 (11) 0 0 11
Vomiting 6 (11) 0 0 11
Hypertension 4 (8) 1 (2) 0 9
Weight loss 4 (8) 1 (2) 0 9
Low mood 4 (8) 1 (2) 0 9
Chest pain 2 (4) 1 (2) 0 6
Thrombocytopenia 1 (2) 1 (2) 0 4
Back pain 1 (2) 0 2
MI 0 1 (2) 2
Knee swelling 1 (2) 0 2
Allergic reaction 1 (2) 0 2
All related or possibly related grade 3 or grade 4 adverse events are shown, together 
with any grade adverse events occurring at a frequency of more than 10%, for the 53 
evaluable patients. Events were graded according to Common Toxicity Criteria Adverse 
Events version 3.
PPE, palmar-plantar erythrodysesthesia; MI, myocardial infarction.
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had nonepithelioid histology, which is associated with poor 
prognosis. This is a relatively high proportion compared with 
large published trials in this disease.3,4
The anti-VEGF antibody bevacizumab has been inves-
tigated in combination with gemcitabine/cisplatin chemo-
therapy in a placebo-controlled randomized phase 2 study. 
The primary endpoint was not met, but the results suggest a 
negative prognostic role for circulating VEGF.11 The modest 
activity of antiangiogenic drugs in this disease, despite prom-
ising preclinical rationale, may reflect the absence of any bio-
marker selection strategy for clinical use of these agents.
Sorafenib was well tolerated in this trial, with adequate 
supportive medication. The toxicity profile observed was sim-
ilar to that previously reported for sorafenib. Fatigue, rash, and 
palmar-plantar erythrodysesthesia were common, resulting 
in relatively high rates of dosage interruption and reduction. 
However, with these interventions, and supportive medication 
for common toxicities, discontinuation because of intolerable 
toxicity occurred in only 21% of patients.
The main limitation of this study was absence of ran-
domization.36 This in part reflects the difficulty in defining a 
standard of care in this setting, although the relative rarity of 
the disease justifies carefully designed single-arm studies to 
explore activity for new treatment approaches in mesotheli-
oma.34 Many patients with mesothelioma remain fit even after 
completion of first-line chemotherapy so that placebo-con-
trolled trials face the challenge of low patient acceptability, 
which can compromise recruitment.37 However, strategies do 
exist to minimize placebo exposure in future trials.38
In conclusion, sorafenib is well tolerated in mesothelioma. 
It has moderate clinical activity when benchmarked against 
pooled historical data.28 A median PFS of 5.1 months compares 
favorably with other VEGFR inhibitors in patients previously 
treated with first-line platinum combination chemotherapy.
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FIGURE 1.  Kaplan–Meier plots for (A), PFS and (B), OS. 
Fifty-three patients provided data for both analyses. Median 
PFS was 5.1 months (95% CI: 3.5–6.7 months), with 36% 
(95% CI: 22%–49%) of patients progression-free at 6 
months. Median OS was 9.0 months (95% CI: 6.7–11.3 
months). PFS, progression-free survival; OS, overall survival; 
CI, confidence interval.
FIGURE 2.  Best response by Response Evaluation Criteria 
in Solid Tumors criteria modified for mesothelioma. Each bar 
represents an individual patient. Two patients were not evalu-
able because of nontarget lesion progression at 8 weeks, and 
12 patients did not complete the first response assessment 
at 8 weeks (white = partial response; black = stable disease; 
hatched = progressive disease).
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